Relationship between FEV

Bronchiolitis obliterans syndrome Chronic lung allograft dysfunction Disease burden FEV1 Hematopoietic stem cell transplantation complications Lung transplantation complications Mortality

Journal

Respiratory medicine
ISSN: 1532-3064
Titre abrégé: Respir Med
Pays: England
ID NLM: 8908438

Informations de publication

Date de publication:
11 2021
Historique:
received: 24 02 2021
revised: 24 08 2021
accepted: 05 09 2021
pubmed: 14 9 2021
medline: 8 2 2022
entrez: 13 9 2021
Statut: ppublish

Résumé

Bronchiolitis obliterans syndrome (BOS) is one of the most severe complications and the leading cause of late mortality and morbidity after lung transplantation (LT) and allogeneic hematopoietic stem cell transplantation (allo-HSCT). No approved treatment for BOS is available. This review aimed to systematically identify and summarise the findings regarding the relationship between FEV A systematic literature search was performed in the Medline, Embase and Cochrane reviews databases. Of the 501 potential studies identified 25 met inclusion criteria and were analysed. Overall, 13 studies reported a relationship between FEV The systematic literature review identified studies and findings that support a relationship between FEV

Sections du résumé

BACKGROUND
Bronchiolitis obliterans syndrome (BOS) is one of the most severe complications and the leading cause of late mortality and morbidity after lung transplantation (LT) and allogeneic hematopoietic stem cell transplantation (allo-HSCT). No approved treatment for BOS is available. This review aimed to systematically identify and summarise the findings regarding the relationship between FEV
METHODS
A systematic literature search was performed in the Medline, Embase and Cochrane reviews databases. Of the 501 potential studies identified 25 met inclusion criteria and were analysed.
RESULTS
Overall, 13 studies reported a relationship between FEV
CONCLUSIONS
The systematic literature review identified studies and findings that support a relationship between FEV

Identifiants

pubmed: 34517199
pii: S0954-6111(21)00316-4
doi: 10.1016/j.rmed.2021.106608
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

106608

Informations de copyright

Copyright © 2021 Elsevier Ltd. All rights reserved.

Auteurs

Robert Kemp (R)

Breath Therapeutics, a Zambon Company, Menlo Park, CA, USA.

Iwona Pustulka (I)

HEOR, Creativ-Ceutical, Kraków, Poland.

Gerhard Boerner (G)

Breath Therapeutics, a Zambon Company, Munich, Germany.

Beata Smela (B)

HEOR, Creativ-Ceutical, Kraków, Poland.

Emilie Hofstetter (E)

HealthStrat Consulting, Munich, Germany.

Yuliya Sabeva (Y)

HEOR, Creativ-Ceutical, Sofia, Bulgaria.

Clément François (C)

HEOR, Creativ-Ceutical, Paris, France. Electronic address: clement.francois@creativ-ceutical.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH